Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

Dr. Edwin L. Parsley, Chief Medical Officer of the Company, said: "Previously-announced positive results from multiple randomized, placebo-controlled studies of vepoloxamer in a well-established model of chronic heart failure, including a repeat-treatment study, as well as recommendations from medical experts in the field, strongly support clinical development of vepoloxamer in this setting. If the promising results observed in non-clinical studies translate to patients with chronic heart failure, vepoloxamer may offer a novel way of directly improving left ventricle contractile function by restoring cardiomyocyte membrane integrity and increasing cardiomyocyte survival. Significantly, in this Phase 2 study, vepoloxamer will be administered over 3 hours in an outpatient setting, as opposed to the 49-hour administration in our sickle cell disease studies, which will help demonstrate its practical utility for chronic heart failure patients. We intend to collect echocardiographic data on parameters such as ejection fraction as well as biomarkers associated with clinical outcomes such as ultra-high sensitivity troponin I and NT-proBNP, as these metrics were improved in a statistically significantly manner in previously-announced heart failure models."

Brian M. Culley, Chief Executive Officer of the Company, added: "We are pleased to have initiated this 150-patient Phase 2 study, which, notably, is testing a new formulation of vepoloxamer. We designed the new formulation to be more suitable for heart failure patients and have filed a provisional patent application. We now have multiple pending patent applications, including a new formulation application and a new composition of matter application, which would provide market protection for vepoloxamer in the setting of heart failure. In addition, the new formulation is distinct from our sickle cell formulation, which may provide important commercial advantages."